Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Narmadha Rathinasamy"'
Autor:
Vanita Noronha, George Abraham, Vijay Patil, Amit Joshi, Nandini Menon, Abhishek Mahajan, Amit Janu, Srushti Jain, Vikas T Talreja, Akhil Kapoor, Gunjesh Kumar Singh, Satvik Khaddar, Kushal Gupta, Narmadha Rathinasamy, Sujay Srinivas, Amit Agrawal, Pradeep Ventrapati, Kumar Prabhash
Publikováno v:
Cancer Medicine, Vol 10, Iss 5, Pp 1525-1534 (2021)
Abstract Background Checkpoint inhibitors (Nivolumab and Pembrolizumab) are approved for multiple indications in solid tumors. However access to these therapies is limited in low and middle income countries. Hence we performed an audit to identify ac
Externí odkaz:
https://doaj.org/article/5b5c8311ba364527bdcb8ecc4d6fbd9b
Autor:
Narmadha Rathinasamy, Santosh Menon, Gagan Prakash, Nandini Menon, Mahendra Pal, Ganesh Bakshi, Vanita Noronha, Kumar Prabhash, Vedang Murthy, Nilesh Sabale, Archi Agrawal, Amit Joshi
Publikováno v:
Clinical Genitourinary Cancer. 21:124-127
Autor:
Satvik Khaddar, Nandini Menon, Amit Agrawal, Kumar Prabhash, Vanita Noronha, Abhishek Mahajan, Vijay Patil, K. Gupta, George Abraham, Sujay Srinivas, Akhil Kapoor, Vikas Talreja, Narmadha Rathinasamy, Amit Janu, Gunjesh Kumar Singh, Pradeep Ventrapati, Srushti Jain, Amit Joshi
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 5, Pp 1525-1534 (2021)
Cancer Medicine, Vol 10, Iss 5, Pp 1525-1534 (2021)
Background Checkpoint inhibitors (Nivolumab and Pembrolizumab) are approved for multiple indications in solid tumors. However access to these therapies is limited in low and middle income countries. Hence we performed an audit to identify accessibili